Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin

J Perinat Med. 2005;33(6):561-3. doi: 10.1515/JPM.2005.100.

Abstract

Parvovirus B19-infected hydrops fetalis was treated using gammaglobulin injection into the peritoneal cavity (GIFPeC) with B19-IgG-rich immunoglobulin. Fetal anemia and hydrops resolved, and B19-DNA in fetal ascites decreased despite no change in maternal B19-IgG or B19-DNA. Gammaglobulin injection into the peritoneal cavity is thus useful for treating hydrops fetalis while avoiding intrauterine blood-transfusion risks.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia / diagnosis
  • Anemia / etiology
  • Anemia / therapy
  • Antibodies, Viral / administration & dosage
  • Antibodies, Viral / therapeutic use
  • Erythema Infectiosum / complications
  • Erythema Infectiosum / congenital*
  • Erythema Infectiosum / diagnosis
  • Erythema Infectiosum / therapy*
  • Female
  • Fetal Diseases / diagnosis
  • Fetal Diseases / therapy*
  • Humans
  • Hydrops Fetalis / diagnosis
  • Hydrops Fetalis / etiology
  • Hydrops Fetalis / therapy
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / therapeutic use
  • Infant, Newborn
  • Injections, Intraperitoneal
  • Male
  • Parvovirus B19, Human* / immunology
  • Parvovirus B19, Human* / pathogenicity
  • Pregnancy
  • Pregnancy Complications, Infectious / diagnosis
  • Prenatal Diagnosis
  • gamma-Globulins / administration & dosage
  • gamma-Globulins / therapeutic use*

Substances

  • Antibodies, Viral
  • Immunoglobulin G
  • gamma-Globulins